UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - Therapeutic Development and Screening Resource

UAB 儿童囊性肾病核心中心 (UAB-CCKDCC) - 治疗开发和筛查资源

基本信息

  • 批准号:
    10218165
  • 负责人:
  • 金额:
    $ 14.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-20 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT (CORE D) It is the goal of the UAB-Childhood Cystic Kidney Disease Core Center (CCKDCC) to work with the other U54 PKD Centers (RTCC), under the direction of the U24 Coordinating Center Site (U24-CCS) to reduce obstacles in cystic kidney disease research leading to more rapid translational studies by PKD Consortium Members and ultimately to the development of novel therapeutics. The UAB-CCKDCC has assembled a multidisciplinary team of researchers to carry out these goals and actively recruit new and established investigators to the field. The Center will help address the limitations associated with the small CCKD patient population available at individual intuitions by providing access to clinical data and biomaterial from human CCKD patients from across the Americas. The Center will focus on the development of resources to analyze cilio-cystic disease protein function, localization, and interactions. The Center will generate and provide researchers with patient relevant models of CCKD and establish methodology to utilize these models to ascertain the efficacy of candidate therapies to slow disease progression using a standardized, cost-effective, and longitudinal imaging strategy. The resources provided by the CCKDCC will help address several of the most significant hurdles slowing the development of therapeutic approaches and strategically recruit new scientists into the field. The Therapeutics Development and Screening Core (Core D) will coordinate efforts with other U54-PKD Centers, under the direction of the U24-CCS and NIDDK to become a shared national resource facility in which a PKD Consortium member can rapidly evaluate the ability of a candidate therapeutic drug to reverse alterations in pathways commonly associated with CCKD gene mutations and to prevent cyst initiation and expansion and renal function loss. This centralized resource is designed to accelerate discovery research in CCKDs in partnership with the UAB-CCKDCC In vitro and In vivo Bioassay and Model Development Resources (Cores B and C). Integration of these resources with clinical and genetic data and biological specimens from patients with CCKDs, as well as the US node of ADPedKD (a multicenter observational study of childhood ADPKD) compiled by the Clinical, Translational, and Biorepository Resource (Core A) will directly inform the development of new, targeted interventional strategies for patients with CCKDs.
摘要(核心d)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michal Mrug其他文献

Michal Mrug的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michal Mrug', 18)}}的其他基金

Intra-renal T-cell heterogeneity in ADPKD patients
ADPKD 患者肾内 T 细胞异质性
  • 批准号:
    10516046
  • 财政年份:
    2019
  • 资助金额:
    $ 14.06万
  • 项目类别:
Intra-renal T-cell heterogeneity in ADPKD patients
ADPKD 患者肾内 T 细胞异质性
  • 批准号:
    10292929
  • 财政年份:
    2019
  • 资助金额:
    $ 14.06万
  • 项目类别:
Intra-renal T-cell heterogeneity in ADPKD patients
ADPKD 患者肾内 T 细胞异质性
  • 批准号:
    10044403
  • 财政年份:
    2019
  • 资助金额:
    $ 14.06万
  • 项目类别:
Pathobiology of Complement C3 effects in ADPKD
ADPKD 中补体 C3 作用的病理学
  • 批准号:
    8862170
  • 财政年份:
    2014
  • 资助金额:
    $ 14.06万
  • 项目类别:
Pathobiology of Complement C3 effects in ADPKD
ADPKD 中补体 C3 作用的病理学
  • 批准号:
    9339535
  • 财政年份:
    2014
  • 资助金额:
    $ 14.06万
  • 项目类别:
Pathobiology of Complement C3 effects in ADPKD
ADPKD 中补体 C3 作用的病理学
  • 批准号:
    8734856
  • 财政年份:
    2014
  • 资助金额:
    $ 14.06万
  • 项目类别:
Mechanisms of C3 effects in ARPKD pathogenesis
C3 在 ARPKD 发病机制中的作用机制
  • 批准号:
    9107445
  • 财政年份:
    2013
  • 资助金额:
    $ 14.06万
  • 项目类别:
Mechanisms of C3 effects in ARPKD pathogenesis
C3 在 ARPKD 发病机制中的作用机制
  • 批准号:
    8881161
  • 财政年份:
    2013
  • 资助金额:
    $ 14.06万
  • 项目类别:
Mechanisms of C3 effects in ARPKD pathogenesis
C3 在 ARPKD 发病机制中的作用机制
  • 批准号:
    8576371
  • 财政年份:
    2013
  • 资助金额:
    $ 14.06万
  • 项目类别:
Mechanisms of C3 effects in ARPKD pathogenesis
C3 在 ARPKD 发病机制中的作用机制
  • 批准号:
    8713990
  • 财政年份:
    2013
  • 资助金额:
    $ 14.06万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 14.06万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 14.06万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 14.06万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 14.06万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 14.06万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 14.06万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 14.06万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 14.06万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 14.06万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 14.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了